Patient description: Patient A is a 30-year-old male who was admitted to the hospital after 10 days of cough, profuse nocturnal sweating and loss of appetite. He had traveled to India 1 months ago and has not any positive history of TB vaccination. He is a previously healthy man, working as an engineer in a high tech company. He doesn't smoke o use any illicit drugs. He was febrile (38 c) with heart rate of 115 b/min, respiratory rate of 22, BP of 125/75 mmHg and O2 sat of 97%. Chest X-ray showed infiltrate in the middle of left lung with diameter of 1.8 cm with signs of cavitation. The sputum smear revealed positive sputum culture for Mycobacterium tuberculosis which are sensitive of the first-line TB drugs (isoniazid, streptomycin, rifampicin and ethambutol). Lab study is reported bellow: Hgb: 13 g/dl WBC: 14000 /mm3 Plt: 300000 /ml AST: 13 U/L ALT: 15 U/L Alk P: 53 U/L Bill total: 0.6 mg/dl Na: 137 mEq/l K: 4 mEq/l Creatinine: 0.5 mg/dl BUN: 10 mg/dl ESR: 120 mm/hr

Clinical trial eligibility criteria: eligible ages (years): 20.0-999.0,  Pulmonary Tuberculosis Multidrug Resistant Tuberculosis Extensively Drug Resistant Tuberculosis Males and females age 20 and above Documented pulmonary tuberculosis at screening Radiographic evidence of tuberculous disease of the lung(s) History of chronic, AFB positive sputum smears and culture positive TB Mycobacterium species identification as Mycobacterium tuberculosis Confirmed resistance to INH, RIF, kanamycin, ofloxacin, and moxifloxacin by genotypic or phenotypic testing OR subjects with documented failure to respond to treatment despite DST susceptibility Failure to respond (after at least 6 months) to a anti-TB drug regimen including any known active agents Willingness to be an inpatient until 2 consecutive AFB-negative sputum smears When an outpatient, willing to come back for weekly tests and scheduled follow-up visits Willingness to have samples stored Ability and willingness to give written or oral informed consent  Subjects below 20 years of age Subjects who have previously been on LZD Women of childbearing potential, who are pregnant, breast feeding, or unwilling to avoid pregnancy (i.e., the use of appropriate contraception including oral and subcutaneous implantable hormonal contraceptives, condoms, diaphragm, intrauterine device (IUD), or abstinence from sexual intercourse). [Note: Prospective female participants of childbearing potential must have negative pregnancy test (urine) within 48 hours prior to study entry.] Men who are unwilling to use contraceptives or practice abstinence People with any of the following in their current medical assessments: Absolute neutrophil count less than 1000 cells/mL White blood cell count (WBC) less than 3.0 X 10(3)/microL Hemoglobin less than 7.0 g/dL Platelet count less than 75,000 cells/mm(3) Serum creatinine greater than 2.0 mg/dL Aspartate aminotransferase (AST or SGOT) greater than 100 IU/L Alanine aminotransferase (ALT or SGPT) greater than 100 IU/L Total bilirubin greater than 2.0 mg/dL Moderate or severe peripheral or optical neuropathy (or a history of) HIV-1 or HIV-2 infection Systemic lupus erythematosus, rheumatoid arthritis, or other connective tissue disease Patients who, in the investigator's judgment, are too ill to participate in the study History of allergy or serious adverse reaction to the LZD formulation used in this study Patients with anticipated surgical intervention The use of any of the following drugs within 30 days prior to study or anticipated use of these drugs within the next 60 days: (Please not, bronchodilators and cough syrup (or similar cough medicines) are allowed before and during the study if blood pressure is monitored regularly, per Contraindications, p.12, of the Zyvox Package Insert.) Selective serotonin reuptake inhibitors (SSRIs) Monoamine oxidase inhibitors (MAOIs) Systemic cancer chemotherapy Systemic corticosteroids Systemic investigational agents Antiretroviral medications Growth factors HIV vaccines Immune globulin Interleukins Interferons The need for ongoing therapy with antidepressants (SSRI, MAOI), hydroxyzine, dopaminergic agents (such as Sinemet, dopamine, and dobutamine), lithium, cyclosporine, tacrolimus, sirolimus, and levodopa (such as sinemet) while on study drug Any other serious systemic illness requiring treatment and/or hospitalization until subject either completes therapy or is clinically stable on therapy for at least 14 days prior to study entry Patients who the physician has reason to believe may have been non-compliant in the previous 12 months of treatment Subjects who meet the for main study are eligible for the substudy for main study apply to the substudy with the exception that subjects with uncontrolled diabetes mellitus will be excluded from the substudy. The study physician may decide that a patient is healthy enough to participate in the main study but not the sub-study